Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: Design, development and place in therapy

Timothy E Albertson, Samuel W. Bullick, Michael Schivo, Mark E Sutter

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenatate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.

Original languageEnglish (US)
Pages (from-to)4047-4060
Number of pages14
JournalDrug Design, Development and Therapy
Volume10
DOIs
StatePublished - Dec 14 2016

Keywords

  • Asthma
  • Combined inhaler
  • Dry powder inhaler
  • Fluticasone furoate/vilanterol trifenatate
  • Inhaled corticosteroid
  • Long-acting beta agonist
  • Persistent asthma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: Design, development and place in therapy'. Together they form a unique fingerprint.

  • Cite this